Instil’s bispecific dream is over
The company hands its PD-L1 x VEGF bispecific back to ImmuneOnco.
One ricochet of the ivonescimab bullet
The small cap biotech Instil Bio tries to follow in Summit’s slipstream.
The company hands its PD-L1 x VEGF bispecific back to ImmuneOnco.
The small cap biotech Instil Bio tries to follow in Summit’s slipstream.
